T
Todd R. Golub
Researcher at Harvard University
Publications - 454
Citations - 234100
Todd R. Golub is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Gene expression profiling. The author has an hindex of 164, co-authored 422 publications receiving 201457 citations. Previous affiliations of Todd R. Golub include Rush University Medical Center & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Imaging of multiple mRNA targets using quantum dot based in situ hybridization and spectral deconvolution in clinical biopsies
Eleni Tholouli,Judith A. Hoyland,Dolores Di Vizio,Fionnuala O'Connell,Sarah A. MacDermott,David Twomey,Richard M. Levenson,John A. Liu Yin,Todd R. Golub,Massimo Loda,Richard J. Byers +10 more
TL;DR: A methodology of multiplexed in situ hybridization (ISH) using a novel combination of quantum dot (QD)-labeled oligonucleotide probes and spectral imaging analysis in routinely processed, formalin-fixed paraffin embedded human biopsies is described.
Journal ArticleDOI
Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines
Cord C. Uphoff,Roderick A.F. MacLeod,Sabine A. Denkmann,Todd R. Golub,Arndt Borkhardt,J. W. G. Janssen,Hans G. Drexler +6 more
TL;DR: The recurrent (12;21)(p13;q22) translocation fuses the two genes TEL and AML1 that have previously been cloned from translocation breakpoints in myeloid leukemias and provides a further example of the paradigm of TEL-AML1 fusion accompanied by deletion of the residual TEL allele.
Journal ArticleDOI
Genome-wide views of cancer.
TL;DR: Nearly coincident with the publication of the article by Hedenfalk et al. in this issue of the Journal are reports of the complete DNA sequence of the human genome.
Posted ContentDOI
Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration
James M. McFarland,Zandra V. Ho,Guillaume Kugener,Joshua M. Dempster,Phillip G. Montgomery,Jordan Bryan,John M. Krill-Burger,Thomas M Green,Francisca Vazquez,Jesse S. Boehm,Todd R. Golub,William C. Hahn,David E. Root,Aviad Tsherniak +13 more
TL;DR: This model is applied to individual large-scale datasets and shows that it substantially improves estimates of gene dependency across a range of performance measures, including identification of gold-standard essential genes as well as agreement with CRISPR-Cas9-based viability screens.
Journal ArticleDOI
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability
Tuoping Luo,Kristina Masson,Jacob D. Jaffe,Whitney Silkworth,Nathan T. Ross,Christina Scherer,Claudia Scholl,Stefan Fröhling,Steven A. Carr,Andrew M. Stern,Stuart L. Schreiber,Todd R. Golub +11 more
TL;DR: The development of selective, low nanomolar inhibitors of STK33’s kinase activity are described, which failed to kill KRAS-dependent cells and are most consistent with the view that inhibition of STk33‘sKinase activity does not represent a promising anti-KRAS therapeutic strategy.